Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
was upgraded at Morgan Stanley from Equal-weight to Overweight. $34 price target. Apixaban is performing well, highlighting the company's solid pipeline.
upgraded at UBS from Neutral to Buy. $47.50 price target. Secular growth is likely to enter a new phase.
rated new Outperform at BMO Capital. $340 price target. Company has strong earnings potential and trades at a reasonable valuation.
downgraded at Sterne from Buy to Neutral. Valuation call, based on a $26 price target.
downgraded at Morgan Stanley from Overweight to Equal-weight. Company is facing margin pressure.
upgraded at Argus from Hold to Buy. $111 price target. Freight division is performing better.
( FFIX) downgraded at JPMorgan from Overweight to Neutral. $105 price target. Signs of revenue stabilization.
rated new Sell at Maxim. $85 price target. Long-term earnings power is threatened by lower polysilicon prices.
rated new Market Perform at BMO. $135 price target. Stock is already pricing in the company's growth potential.
rated new Neutral at Goldman. $43 price target. Attractive revenue growth with a strong competitive position.
rated new Buy at UBS. $190 price target. Company sells best of breed business intelligence platforms.
downgraded at Weeden from Buy to Hold. $28 price target. Stock lacks near-term catalysts.
rated new Market Perform at BMO Capital. Valuation call, based on a $28 price target.
( NLC) downgraded at Goldman from Neutral to Sell. $28 price target. Company faces rising petrochemical costs.
rated new Outperform at BMO. DBI merger should help create value. $44 price target.
downgraded at JPMorgan from Overweight to Neutral. $27 price target. Near term catalysts have played out.
downgraded at Weeden from Hold to Buy. $75 price target. Stock has underperformed its peers and the floater market should improve.
End of report.
This article was written by a staff member of TheStreet.